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BACKGROUND: This supplement presents a wide range of observations, reviews, novel research and analyses underpinning the National
Awareness and Early Diagnosis Initiative (NAEDI). The preceding three papers present and discuss different aspects of the data from
European cancer survival comparison studies. I conclude here by attempting to quantify the extent to which delayed diagnosis in
England accounts for observed survival differences and by outlining areas for further research.
METHODS: Analysis of indirect evidence related to late diagnosis, surgical intervention rates and utilisation of radiotherapy and
chemotherapy in England and other European countries in the late 1990s for breast, colorectal and lung cancer.
RESULTS: Late diagnosis was almost certainly a major contributor to poor survival in England for all three cancers. Low surgical
intervention rates are very likely to have contributed to low survival rates for lung cancer and possibly for the other two cancers. Any
differences in the use of radiotherapy or chemotherapy are likely to have had only a minor impact on survival differences.
CONCLUSION: Between 5000 and 10000 deaths within 5 years of diagnosis could be avoided every year in England if efforts to
promote earlier diagnosis and appropriate primary surgical treatment are successful. Detailed international benchmarking studies are
to be recommended.
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In an accompanying paper in this supplement of the British
Journal of Cancer, Abdel-Rahman et al (2009) have estimated the
numbers of cancer deaths that would have been avoided each year
in Britain (England, Wales and Scotland) if survival had matched
that observed elsewhere in Europe. For patients diagnosed over the
15-year period (1985–1999), around 6000–7000 deaths a year that
occurred within 5 years of diagnosis would have been avoided if
survival in Britain had matched the mean for Europe.
If survival in Britain had matched the best in Europe, around
13000 premature cancer deaths (those within 5 years of diagnosis)
would have been avoided each year among patients diagnosed in
the 10 years between 1985 and 1994 and around 11500pa for those
diagnosed in the years 1995–1999. It is important to note that the
‘highest’ European survival rate was defined conservatively on the
basis of the average of the three countries with highest survival
rates, excluding Austria and Switzerland at whose data criticisms
have been levelled.
The analysis by Abdel-Rahman et al (2009) does not,
however, attempt to provide estimates of the proportions of
these avoidable deaths that may be attributed to late diagnosis,
inferior treatment or other factors. Building on the study by
Abdel-Rahman et al (2009) and the analyses presented by
Thomson and Forman (2009) and Møller et al (2009), I explore
the contributions of different factors to the reported numbers of
avoidable deaths for the three cancers with the highest UK
mortality and suggest further action and research that might
enable us to elucidate this further.
Breast, colorectal and lung cancer accounted for nearly half of
the overall numbers of deaths that could have been avoided each
year if survival had matched the highest in Europe for cancers
diagnosed between 1995 and 1999 (breast cancer – around 2000pa;
colorectal cancer – around 1700pa and lung cancer – around
1300pa). Prostate cancer has been excluded from the current
analysis as it is highly likely that differences in reported 5-year
survival rates relate to differences in prostate-specific antigen
testing rates. Avoidable deaths within 5 years of diagnosis may
largely reflect a lead-time effect.
POTENTIAL FACTORS ACCOUNTING FOR SURVIVAL
DIFFERENCES
Several factors could potentially contribute to international
variations in survival rates. These include the following:
  Longer delays leading to more advanced stage of disease at
diagnosis in some countries.
  Differences in uptake of screening opportunities for some
cancers.
  Access to and quality of primary and adjuvant treatments for
cancer.
  Differences in prevalence of co-morbidities between countries.
  Differences in the biology of cancer between countries.
Unfortunately, direct international comparative data are cur-
rently unavailable for most of these factors (the possible exception
being screening). However, in considering possible explanations
for the worse survival rates observed in the United Kingdom,
different strands of indirect evidence can be used. First, there are
positive indicators of delay and advanced stage contributing to
poor survival. Poor 1-year survival rates are generally taken to be
an indicator of more advanced disease at diagnosis, though
differences in co-morbidities or biology could also contribute.
Second, the likely magnitude of the contribution of other factors
(e.g. access to and quality of primary treatments) can be explored.
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to breast, colorectal and lung cancer.
BREAST CANCER
There are no studies, which directly compare the extent of delays
in diagnosis of breast cancer in the United Kingdom with those in
other countries. However, there is evidence that patients in the
United Kingdom tend to present with more advanced disease (Sant
et al, 2003). There is also strong evidence for breast cancer that
longer delays are associated with more advanced disease and with
poorer survival (Richards et al, 1999). Women whose overall
duration of symptoms is between 3 and 6 months are estimated to
have a 7% lower 5-year survival rate than those with shorter
duration of symptoms (Richards et al, 1999).
The study by Sant et al (2003) involved two cancer registries in
the United Kingdom (Thames and Mersey) and related to patients
diagnosed in 1990–1992. The proportion of patients presenting
with metastatic disease was considerably higher in the Thames
Cancer Registry region (10.6%) than in the overall study group
(6.2%), which involved registries in Italy, Spain, France, Estonia
and the Netherlands. The proportion of patients undergoing
surgery was also lower in Thames (83%) and Mersey (88%) than
for the group as a whole (90%). Multiple regression analyses of
relative survival showed that adjustment for disease stage and
surgery greatly reduced the excess risk observed in the two UK
registries. The authors concluded that a major reason for the
comparatively low survival of breast cancer patients in England
was more advanced stage at diagnosis.
Further indirect evidence that advanced stage at diagnosis is a
major explanatory factor for the poor survival rates in England
comes from the EUROCARE 4 study. As described by Thomson
and Forman (2009), 1-year survival rates for women with breast
cancer in the United Kingdom were significantly below the
European average (91.8 vs 93.8%), whereas 5-year survival
conditional on surviving 1 year (5|1 survival) was similar to the
average (84.2 vs 84.6%).
Surgery remains the mainstay of curative treatment for breast
cancer. Patients presenting with inoperable disease have a much
worse prognosis than those with operable disease. However,
among patients receiving breast surgery, the extent of surgery and
the completeness of tumour excision have a relatively minor
impact on 5-year survival rates. In addition to this, there is no clear
evidence that the quality of breast surgery in the United Kingdom
was inferior to that in other European countries at the time of the
EUROCARE 4 study (1995–1999). However, a recent study from
the Eastern Region of England has raised concerns as to whether
all women with breast cancer who might benefit from surgery are
receiving it (Wishart et al, 2009). In that study, 27% of women over
the age of 70 years diagnosed between 1999 and 2003 did not
undergo surgery. This figure excluded patients with stage 4
disease.
Radiotherapy is widely used as an adjunct to breast surgery both
in women undergoing breast conserving operations and those who
are at high risk of local recurrence after mastectomy. Overviews of
randomised trials of the impact of radiotherapy (given in addition
to breast conserving surgery or mastectomy) have shown highly
significant reductions in local recurrence rates and moderate
effects on long-term (15 years) breast cancer mortality. Some effect
on mortality related to the use of radiotherapy is evident within
5 years of diagnosis (EBCTCG, 2005a; Table 1).
The large majority of women undergoing breast conserving
surgery in the United Kingdom in the late 1990s are likely to have
received radiotherapy, although low radiotherapy capacity may
have led to delays in starting treatment. However, if substantial
numbers of women with node-positive disease undergoing breast
conserving surgery did not receive radiotherapy, this could also
have contributed to poor survival for this group. The impact of any
such undertreatment can be estimated from the effect size
observed in the randomised trials. For example, if 25% of node-
positive patients treated with breast conserving surgery did not
receive radiotherapy (which is likely to be a significant over-
estimate), the overall impact on 5-year survival rates would have
been o0.5%, as these patients only constitute a minority of all
patients with breast cancer. Some women undergoing mastectomy
will also have received radiotherapy to the chest wall, though
comparative figures for the United Kingdom and Europe are not
available. However, given the modest overall impact of radio-
therapy after mastectomy on 5-year survival rates observed in
randomised controlled trials, any differences between the United
Kingdom and Europe are likely at most to have made only a small
contribution to the observed differences in 5-year survival rates
and thus to avoidable deaths within 5 years of diagnosis.
Adjuvant chemotherapy and hormonal therapy for early breast
cancer undoubtedly reduce local recurrence rates and enhance
long-term survival rates (EBCTCG, 2005b). However, the overall
impact of adjuvant chemotherapy on 5-year survival rates for
women with breast cancer has been estimated to be around 1.5%
(Morgan et al, 2004). Thus, any differences in utilisation of
adjuvant chemotherapy between the United Kingdom and Europe
in the period 1995–1999 can only have had a very minor impact on
5-year survival rates – and there is no firm evidence of lower
utilisation in the United Kingdom.
Table 1 Impact of adjuvant therapies on 5-year breast cancer mortality
5-year breast cancer mortality
Without (%) With (%) Difference (%)
Radiotherapy
Breast-conserving surgery (node negative) 8.9 8.0 0.9
Breast-conserving surgery (node positive) 24.3 20.9 3.4
Mastectomy+axillary clearance (no) 12.5 11.3 1.2
Mastectomy+axillary clearance (n+) 34.0 32.1 1.9
Chemotherapy
Polychemotherapy (age o50 years) 20.4 15.7 4.7
Polychemotherapy (age 50–69 years) 21.3 18.7 1.6
Hormonal therapy
Tamoxifen (about 5 years) in ER-positive or ER-unknown disease 11.9 8.3 3.6
Ovarian ablation or suppression in ER-positive or ER-unknown disease 18.4 16.6 1.8
Abbreviations: ER¼estrogen receptor. Note: Figures taken from EBCTCG (2005a,b).
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in randomised trials is significant (Table 1). Tamoxifen will
have been the key adjuvant hormonal treatment in the late
1990s both in the United Kingdom and in Europe. In general,
uptake of hormonal therapies in the United Kingdom, and
Tamoxifen in particular, has been high over the past two decades.
It is, therefore, very unlikely that differences in utilisation of
hormonal therapies will have accounted for observed differences in
survival rates.
Taking all these factors together, there is good evidence that
more advanced stage of breast cancer at diagnosis will have been a
major contributor to avoidable deaths, partly mediated by lower
proportions of patients presenting with operable disease. Under-
utilisation of surgery in older patients with potentially operable
disease may also have been a factor. Differences in the quality of
surgery or in utilisation of radiotherapy or adjuvant chemotherapy
cannot be excluded, but are likely to be minor contributors. There
is no evidence that underutilisation of hormonal therapies was a
factor in the United Kingdom. The relatively high uptake of
screening in the United Kingdom in the late 1990s compared with
that in other European countries should have led to higher survival
rates and, therefore, reduced the estimates of avoidable deaths.
This further suggests that the problems lie among the large
majority of breast cancer patients who presented symptomatically
(around 80% in the late 1990s in the United Kingdom).
COLORECTAL CANCER
As with breast cancer, there is strong evidence that extent of
disease at diagnosis (stage) is a major prognostic factor in patients
with colorectal cancer. Presentation to hospital as an emergency
also carries an adverse prognosis. However, unlike breast cancer,
there is no clear relationship between extent of delay, stage and
survival.
A EUROCARE high-resolution study has examined factors
contributing to variations in survival from colorectal cancer (Gatta
et al, 2000). This study involved patients diagnosed around 1990
from six European countries (Italy, France, the Netherlands, Spain,
United Kingdom and Poland). Two registries in the United
Kingdom participated – Mersey and Thames. Across all participat-
ing registries, the mean 3-year survival rate was 48%. Survival was
lower than average for patients from both of the UK registries
(Mersey 44%, Thames 38%). The proportions of patients with
Dukes A or B disease were below average in both of the UK
registries, and both had a high proportion of deaths within 1
month of diagnosis (Mersey 9%, Thames 16%), even though cases
known to the registries through death certificate only or autopsy
had been excluded. Cox modelling showed that the outcomes for
patients in the United Kingdom were attributable at least in part to
unfavourable stage distribution.
Aside from adverse stage distribution, to what extent might
differences in practice related to surgery, radiotherapy or
chemotherapy account for observed differences in outcomes
between Britain and the countries in Europe with the best survival
rates? A recent national audit of around two thirds of incident
cases of bowel cancer diagnosed in England in 2007 and 2008
showed that 75% underwent some form of surgical treatment, but
that only 60% underwent a major resection (Information Centre
for Health and Social Care, 2009a). Wide variations in major
resection rates were observed between cancer networks. This
suggests that a considerable proportion of patients with colorectal
cancer in England are presenting either at a stage in which the
disease is inoperable or when they are deemed unfit for surgery on
other grounds.
The quality of surgical excision is increasingly being recognised
as a prognostic factor both in rectal cancer (Quirke et al, 2009) and
colonic cancer (West et al, 2008; Hohenberger et al, 2009). Total
mesorectal excision of rectal cancer was pioneered in the United
Kingdom in the late 1980s (Heald and Ryall, 1986). However, it was
adopted into routine clinical practice in some other European
countries during the early 1990s (Wibe et al, 2002; Martling et al,
2005), but not until a decade later in the United Kingdom. This
could certainly contribute to observed differences in survival rates
for rectal cancer between European countries for patients
diagnosed in the late 1990s and the early years of this century.
Radiotherapy (either preoperative or postoperative) has a
significant function in the management of rectal cancer, but not
of colon cancer. In the Swedish Rectal Cancer Trial (1997), the
addition of a short course of pelvic radiotherapy before surgery
resulted in a significant improvement in overall survival at 5 years
(58 vs 48%). However, in the NSABP R-02 study (Wolmark et al,
2000), the addition of postoperative radiation therapy to
chemotherapy in Dukes B and C rectal cancer had no beneficial
effect on survival (though locoregional relapse was reduced).
Differences in utilisation of radiotherapy for rectal cancer between
European countries could, therefore, potentially contribute to
observed differences in 5-year survival rates. However, the extent
of any differences in utilisation is difficult to quantify.
Adjuvant chemotherapy has an established function in the
management of patients with lymph node-positive (Dukes C)
colorectal cancer, but is of uncertain benefit in Dukes B disease.
Morgan et al (2004) estimated that the use of adjuvant
chemotherapy contributes 1.8% to 5-year survival rates for colon
cancers in Australia. This was on the basis of a 5% benefit being
observed in patients with Dukes C disease (35% of those with
colon cancer in Australia), but assumed no benefit in patients with
Dukes B disease (Dube et al, 1997; International Multicentre
Pooled Analysis of Colon Cancer Trials (IMPACT B2) Investiga-
tors, 1999). The comparable estimate for the United States was a
1.0% contribution to 5-year survival. The lower figure for the
United States is attributable to the smaller proportion of patients
presenting with Dukes C disease (21%).
Morgan et al (2004) considered that all patients with Dukes B or
C rectal cancer would benefit from adjuvant chemotherapy and
that the improvement in overall survival with chemotherapy alone
would be 9%. As Dukes B and C patients constituted 60% of all
rectal cancers in Australia, the benefit across all rectal cancers
was 5.4%. The comparable figure for the United States was 3.4%,
on the basis of 38% being Dukes B or C disease. The authors
acknowledge that the figures for rectal cancer in both countries
may be an overestimate as the benefit may only exist for Dukes
C cancer.
There are no available figures to show whether utilisation of
adjuvant chemotherapy for colorectal cancer was lower in the
United Kingdom in the late 1990s than in the European countries
with the highest 5-year survival rates, but this must remain a
possibility. If utilisation in the United Kingdom had been half that
in the countries with the highest survival rates and if the benefits
estimated for Australia had been realised in the ‘best’ European
countries, this would account for a difference of around 0.9% in
5-year survival rates for colon cancer and 2.7% for rectal cancer.
As colon cancer accounts for approximately two thirds of
colorectal cancers, the combined figure would be around 1.5%.
LUNG CANCER
As with breast and colorectal cancer, stage of disease at diagnosis
has a major impact on 5-year survival rates (Mountain, 1997).
Although there have been no direct international comparisons of
extent of delays or of stage at diagnosis for lung cancer, delays
have been reported from a variety of countries (Birring and Peake,
2005) and the finding that 1-year survival rates in England (26.9%)
was well below the European average (36.0%) in the EUROCARE 4
study suggests that late diagnosis is a major factor.
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present with inoperable disease. However, for those whose disease
is amenable to surgery, 5-year survival rates are reasonably good
(Mountain, 1997). Presenting with operable disease and having
access to surgery are, therefore, of very high prognostic
importance in lung cancer.
Although there are no direct international comparisons of lung
cancer resection rates, these have been reported for individual
countries (Table 2). Resection rates in Rotterdam (the Nether-
lands), Sweden, Varese (Italy) and the United States all seem to be
considerably higher than those recently reported from England
and Wales. The figures for England and Wales come from the
National Lung Cancer Audit (the LUCADA database), which
includes approximately 75% of incident cases in these countries
(Information Centre for Health and Social Care, 2009b). They are
considered to be representative of surgical activity in the country
as a whole. It is noteworthy that within England and Wales, there is
wide variation in resection rates between cancer networks (regions
typically covering populations of 1–2.5 million).
The surgery involved in lung cancer is significantly more
invasive and technically complex than, for example, that required
for breast cancer and patient fitness, age and co-morbidities
together with the availability of specialist surgery that are important
factors in decision making and resection rates. As the median age at
diagnosis is around 71 years in the United Kingdom (Information
Centre for Health and Social Care, 2009b) and the majority of lung
cancer patients are smokers or ex-smokers, their rates of cardio-
respiratory co-morbidities are high. These high co-morbidity rates
are likely to apply to lung cancer patients in all countries, though
there is some evidence that co-morbidity rates are higher among
lung cancer patients in the United Kingdom (Imperatori et al, 2005).
It is currently impossible to assess the relative contribution of late
diagnosis, patient fitness and poor access to specialist surgery to the
low resection rates in the United Kingdom. However, it is likely that
failure to identify patients who might be suitable for surgery has
been at least part of the problem. A report from Leicester in England
showed that resection rates doubled after the establishment of a
multidisciplinary team and the appointment of a specialist thoracic
surgeon (Martin-Ucar et al,2 0 0 4 ) .
To what extent are differences in the use of chemotherapy for
lung cancer between the United Kingdom and the countries in
Europe with the highest survival rates likely to impact on 5-year
survival rates? From the National Lung Cancer Audit, we know that
only 62% of patients with small cell lung cancer (SCLC) were
reported as receiving chemotherapy and it is very likely that this
proportion is significantly higher elsewhere in Europe. However,
5-year survival from SCLC is very low in all countries. Among
patients with non-small cell lung cancer, utilisation of adjuvant
chemotherapy will undoubtedly be lower than that in countries
with high resection rates. However, the number of patients
benefiting would be small. It might, therefore, be reasonable to
estimate that the gap in 5-year survival rates between the United
Kingdom and the best in Europe would be narrowed by 0.5–1.0%,
if chemotherapy utilisation was the same. This would, in turn,
require more patients to be diagnosed at an operable stage and be
referred for surgery.
DISCUSSION
For breast, colorectal and lung cancers, 1-year survival in England
is below the European average and considerably below that
observed in countries with the highest survival in Europe. For
breast and colorectal cancer, there is good evidence, albeit relating
to the early 1990s, that the poor 5-year survival observed in
England was at least in part attributable to patients having more
advanced disease at diagnosis. For lung cancer there is increasing
evidence, as outlined above, that fewer patients in England (and
Wales) undergo lung resection than in other countries. It seems
likely that this is due to a combination of late diagnosis and failure
to identify and refer patients who are suitable for surgery. Low
rates of surgical intervention for breast and colorectal cancer may
also contribute to poor survival rates, though comparative data are
currently lacking.
Chemotherapy given to patients presenting with metastatic
breast, colorectal or lung cancer is likely to have had only a
marginal impact on 5-year survival rates for each cancer, as
survival is poor whether or not a patient receives chemotherapy.
Differential use of adjuvant chemotherapy for each cancer type
between countries could contribute to the overall gap in survival
rates. However, from the estimates made by Morgan et al (2004),
the overall contribution of chemotherapy to 5-year survival seems
to be relatively small. Any differences because of variations in
utilisation of adjuvant chemotherapy will inevitably be smaller.
Similarly, differences in utilisation of radiotherapy are likely to
have only a modest impact on 5-year survival.
In conclusion, late diagnosis and low surgical intervention rates
seem to be by far the most important factors underlying the poor
5-year survival rates observed in England. Although exact
estimates are impossible, it seems highly likely that these factors
accounted for the large majority of the avoidable deaths in England
observed during the 1990s for patients with breast, colorectal and
lung cancer. There is no reason to think that the same factors will
not apply in some, if not all, other cancers for which survival in
England is below the European average. It is, therefore, likely that
most (i.e. between 5000 and 10000) of the avoidable deaths
observed each year in the late 1990s when assessed against the
highest survival in Europe were attributable to late diagnosis,
combined with low utilisation of potentially curative treatments.
How are things likely to have changed over the past decade?
One-year survival rates have continued to improve in England for
breast cancer and colorectal cancer and are likely to have
improved in other countries too. Little change has been observed
in 1-year survival for lung cancer. Major progress has been made
over the past decade in England in relation to cutting hospital
waiting times, establishing specialist multidisciplinary teams and
reconfiguring complex surgical services. Screening for breast
cancer has been extended and improved and screening for bowel
cancer has been introduced. However, until very recently much
less attention has been paid to the problem of late diagnosis. Given
the findings outlined in this paper, it is, therefore, likely that the
gap in 5-year survival will have remained substantial.
Efforts now need to be directed at promoting early diagnosis for
the very large number (over 90%) of cancer patients who are
Table 2 Lung cancer resection rates
Reference Location Period Resection rate (%)
Damhuiss and Schutte (1996) Rotterdam (Netherlands) 1984–1992 20
Myrdal et al (2009) Sweden 1995–2003 17.5
Fry et al (1999) USA 1985–1995 27*
Imperatori et al (2005) Varese (Italy) ? 25
Information Centre for Health and Social Care, 2009b England + 2005–2007 9–10.2
Wales 12
*These figures relate to patients for whom a histological diagnosis had been made, rather than to the entire population of lung cancer patients.
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National Awareness and Early Diagnosis Initiative has been
established to coordinate and drive efforts in this area. The size
of the prize is large – potentially 5000 to 10000 deaths that occur
within 5 years of diagnosis could be avoided every year.
This analysis has highlighted the lack of direct comparative data
enabling definitive statements to be made on the reasons for
survival differences between countries and on the numbers of lives
that might be saved through different interventions. Detailed
international benchmarking studies are now needed to explore the
contributions of the factors considered in this paper. Alongside,
up-to-date comparisons of survival, high-resolution studies are
needed to examine potential differences in stage, co-morbidity,
biology and treatments. It would also be valuable to measure
delays in different countries and the factors, which may contribute
to delays. In addition to these benchmarking studies, further
primary research should be encouraged to assess the effectiveness
and cost effectiveness of interventions to promote earlier
presentation.
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